BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival. In recent years, new conditioning regimens have been explored to improve transplantation outcomes in patients with AML. Treosulfan combines a potent immunosuppressive and antileukemic effect with a low toxicity profile. . RESULTS: At a median follow-up of 61 months, the 5-year overall survival, leukemia-free survival, relapse incidence, and nonrelapse mortality rates were 38%, 33%, 42%, and 25%, respectively. The incidence of grade II-IV acute and chronic graft-versus-host disease was 24% (grade III-V, 11%) and 38%, respectively. Only 11 patients (2%) developed veno-occlusive disease, with two deaths (0.4%) from veno-occlusive disease. CONCLUSIONS: Treosulfan-based conditioning regimens provide an acceptable long-term survival with favorable nonrelapse mortality and a very low risk of veno-occlusive disease.
INTRODUCTION
Busulfan-based and total body irradiation (TBI)-based preparative regimens are widely regarded as standard conditioning therapies for allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). [1] [2] [3] [4] [5] A significant challenge in the management of patients with high-risk AML is the relatively high transplantation-related mortality associated with intensive HCT conditioning regimens. Thus, there is a need for conditioning regimens that reduce the incidence of relapse without significantly increasing the risk of transplantation-related mortality.
Traditionally, high-intensity conditioning regimens have been standard practice for eradicating AML with HCT. Busulfan is an effective immunosuppressive and antileukemic agent. However, acute and late toxicities are major challenges associated with this potentially curative therapy. 3, 4, [6] [7] [8] [9] [10] The common myeloablative conditioning regimens used in AML include cyclophosphamide plus TBI, cyclophosphamide plus busulfan, or fludarabine plus busulfan. The use of high-dose busulfan and TBI are associated with substantial hepatic toxicity, pulmonary toxicity, neurotoxicity, and cardiotoxicity. [1] [2] [3] [4] 6, 8 Consequently, it is important to identify less toxic conditioning regimens that maintain the antileukemic, immunosuppressive, and myeloablative characteristics of conventional conditioning therapies.
Treosulfan (a water-soluble, bifunctional alkylating agent) has demonstrated efficacy as an antileukemic and immunosuppressive agent. 11 In contrast to busulfan, treosulfan does not require enzymatic activation and thus bypasses hepatic metabolism. Pharmacokinetic studies of both single and multiple intravenous infusions of treosulfan have exhibited low interpatient and intrapatient variability. [11] [12] [13] In vitro studies have demonstrated strong proapoptotic effects in human AML cells, 11, 14, 15 and work from murine xenograft models has revealed potent in vivo activity of treosulfan against acute and chronic leukemia, human B-lymphoblast and T-lymphoblast cell lines, and various solid tumors, myelomas, and lymphomas. 11, 14, 16 Dose-limiting toxicities of treosulfan include bone marrow suppression, which occurs at a dose of 10 g/m 2 , suggesting that the drug may be effective for HCT conditioning. In clinical trials with autologous HCT, the maximum tolerated cumulative dose of treosulfan could be escalated from 10 to 47 g/m 2 before mucositis, diarrhea, dermatitis, or metabolic acidosis became dose-limiting. 17 In those studies, no episodes of severe hepatotoxicity or central nervous system toxicity were observed. Moreover, treosulfan targets both committed and uncommitted hematopoietic stem cells and thus has profound antileukemic and immunosuppressive properties. 11, 16, 18 Although data are limited, recent published studies have reported encouraging results with acceptable nonhematologic toxicity. 11, 17, [19] [20] [21] [22] [23] [24] However, to date, no large trials have studied the value of treosulfan-based conditioning in HCT as a potential alternative to the commonly used busulfanbased or TBI-based regimens for patients with AML. In this large, registry-based analysis, we report the safety and efficacy of treosulfan-based conditioning for patients with AML who undergo allogeneic HCT.
MATERIALS AND METHODS

Study Design and Data Collection
This is a retrospective, multicenter analysis with data provided by the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) group registry, which is a voluntary working group of more than 500 transplantations centers that are required to report all consecutive stem cell transplantations and follow-ups on an annual basis. Since 1990, registry patients have provided informed consent authorizing the use of their personal information for research purposes. The ALWP of the EBMT group approved this study. The study protocol was approved by the institutional review board at each site and complied with country-specific regulatory requirements. The study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines.
Eligibility criteria for this analysis included adult patients (age 18 years) with AML who received a treosulfan-based conditioning regimen followed by a related or unrelated donor (URD) bone marrow transplantation or granulocyte-colony-stimulating factor-mobilized peripheral blood stem cells transplantation between the years 2000 and 2012 (n 5 520 patients; n 5 19 transplantation centers). Treosulfan was combined with different chemotherapeutic agents, most frequently with fludarabine (94%) or cyclophosphamide (3.5%). The most frequent dose range for treosulfan was from 36 to 42 g/m 2 ( Table 1) 2 ). The variables investigated included recipient and donor characteristics (age, sex, cytomegalovirus serostatus); disease features (including remission status, active/ advanced disease); transplantation-related factors, including conditioning regimen, immunosuppression (in vivo T-cell depletion vs none), stem cell source (bone marrow or peripheral blood), graft-versus-host disease (GVHD) prophylaxis; and outcome variables, including acute and chronic GVHD, relapse, nonrelapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), and causes of death. The choice of conditioning and GVHD prophylaxis depended on transplantation center protocols and strategies for transplantation.
Statistical Analysis
The primary endpoints of this study were LFS and OS. Secondary endpoints included disease relapse incidence Original Article (RI), NRM, engraftment, incidence and severity of acute and chronic GVHD, and risk of veno-occlusive disease of the liver (VOD). 10 The starting point for time-to-event analysis was "date of transplantation." OS was defined as the time to death from any cause, LFS was defined as survival without relapse or progression, and RI was defined as the time to onset of leukemia recurrence. For OS, LFS, and RI, patients were censored at the time of last followup. NRM was the competing risk, and patients who survived in continuous complete remission (CR) were censored at last contact. NRM was defined as death without relapse/progression (relapse was the competing risk). Competing risks considered for GVHD were relapse or death. Standard definitions were used to define remission status. 3, 4, 25 The groups were compared using the chisquare method for qualitative variables, and the MannWhitney test was applied for continuous parameters.
Univariate comparisons were done using the logrank test for OS and LFS and the Gray test for RI, NRM, and GVHD cumulative incidence. Multivariate analyses were performed using Cox proportional hazards model for all endpoints. All factors known as potentially related to the outcomes were included in the model with stepwise selection. All tests were 2-sided. The Type I error rate was fixed at .05 for determination of factors associated with time-to-event outcomes. Statistical analyses were performed using the software packages SPSS 22.0 (IBM Corp., Armonk, NY) and R 3.2.3 (R Development Core Team, Vienna, Austria).
RESULTS
Patient and Transplantation Characteristics
Five hundred twenty patients with AML (median age, 57 years; IQR, 47-63 years) who received a treosulfan-based conditioning regimen followed by HCT from a related donor (n 5 285) or an URD (n 5 235) between 2000 and 2012 were included in this analysis (patient characteristics are summarized in Table 1 ). Patients received treosulfan at a dose of 42 g/m 2 (n 5 396), 36 g/m 2 (n 5 109), or 30 g/m 2 (n 5 15) over 3 days. Four hundred eightyfour patients (94%) received a treosulfan and fludarabinebased conditioning regimen (Table 1 ). In total, 225 patients (43%) were in first CR (CR1), 107 (21%) were in second CR or later (CR2), and 188 (36%) had active/advanced disease (primary refractory, n 5 88) before HCT (Table 1) .
Engraftment
Twenty patients (4%) patients died before day 60 (18 of whom died before day 30) without attaining engraftment. The remaining 490 patients (96%) attained engraftment, with a median day to an absolute neutrophil count (ANC) 500/lL of 16 days (IQR, 13-20 days). The engraftment rates were 94% at day 30 for neutrophils and 93% at day 180 for platelets. One patient had graft rejection. Table 2 ). In multivariate analysis, the factor associated most significantly with increased risk of grade II-IV acute GVHD was active disease (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.11-2.49; P 5 .015). In contrast, T-cell depletion was associated with a reduced risk of acute GVHD (HR, 1.71; 95% CI, 1.17-2.50; P 5 .006) ( Table 3) .
Chronic GVHD
The 5-year cumulative incidence of chronic GVHD was 38% (95% CI, 34%-43%) ( Table 4) . Low-dose treosulfan was associated with a lower incidence of chronic GVHD in univariate analysis (30%; 95% CI, 22%-39%) in the group that received 36 g/m 2 versus 41% (95% CI, 36%-46%) in the group that received 42 g/m 2 (P 5 .03). In multivariate analysis, the risk factor most significantly associated with chronic GVHD was belonging to the poor cytogenetic risk group (HR, 1.52; 95% CI, 1.01-2.27; P 5 .044). Consistent with our findings in acute GVHD, T-cell depletion reduced the risk of chronic GVHD (HR, 0.70; 95% CI, 0.51-0.97; P 5 .03) ( Table 3) .
NRM
The 5-year cumulative incidence of NRM was 25% (95% CI, 21%-29%) ( Table 4) . In univariate analysis, there was Table 4) .
In multivariate analysis, the factors associated with an increased risk of NRM were age at HCT (by 110 years: HR, 1.29; 95% CI, 1.07-1.54; P 5 .0006) and disease status at transplantation (for active/advanced disease: HR, 2.12; 95% CI, 1.37-3.28; P 5 .001). Conversely, a Karnofsky performance status 90% was associated with a decreased risk of NRM (HR, 0.59; 95% CI, 0.40-0.88; P 5 .01) ( Table 3) .
Relapse
The 5-year cumulative RI was 42% (95% CI, 37%-46%) ( Table 4) .
In multivariate analysis, the factors associated with an increased risk of relapse included disease status at transplantation (for active/advanced disease: HR, 3.34; 95% CI, 2.40-4.65; P < .0001), poor cytogenetics (HR, 1.71; 95% CI, 1.19-2.45; P 5 .004), and T-cell depletion (HR, 1.54; 95% CI, 1.06-2.24; P 5 .023). Patients who underwent HCT from a URD and a mismatched-related donor experienced a significantly lower risk of relapse compared with those who underwent HCT from a matched-related donor (URD: HR, 0.49; 95% CI, 0.34-0.71; P 5 .0001; mismatched-related donor: HR 0.56; 95% CI, 0.35-0.91; P 5 .019) ( Table 3) .
LFS
The 5-year LFS rate for the entire cohort was 33% (95% CI, 28%-37%) ( Table 4 , Fig. 1 Abbreviations: CI, confidence interval; CR1, first complete remission; GVHD, graft-versus-host disease.
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July 15, 2017 significantly higher LFS (HR, 0.74; 95% CI, 0.56-0.98; P 5 .037) ( Table 3) .
OS
The 5-year OS rate for the entire cohort was 38% (95% CI, 33%-42%) ( Table 4 , Fig. 1 ). There was no significant association between OS and treosulfan dose (41% [95% CI, 31%-51%] in the 36 g/m 2 group vs 38% [95% CI, 32%-43%] in the 42 g/m 2 group; P 5 .68). This difference remained nonsignificant when we separately analyzed patients in CR1 (65% [95% CI, 51%-79%] vs 53% [95% CI, 45%-61%]; P 5 .28) and those with active/advanced disease (14% [95% CI, 1.3%-26%] vs 18% [95% CI, 12%-25%]; P 5 .97).
In multivariate analysis, the factors associated with inferior OS were disease status at transplantation (for active/advanced disease; HR 2.80; 95% CI, 2.16-3.62; P < .0001) and poor-risk cytogenetics (HR, 1.70; 95% CI, 1.27-2.29; P 5 .0004) ( Table 3) .
Causes of Death
In total, 324 patients died after a median follow-up of 61 months (IQR, 34-84 months). Major causes of deaths were progression or recurrence of the original disease (n 5 149; 48%) and infection (n 5 82; 26%). Causes of deaths are summarized in Table 5 .
VOD
VOD occurred in eleven (2.2%) patients with two deaths (0.4%). VOD was classified as mild (n 5 4), moderate (n 5 2), and severe (n 5 3). VOD classification was missing in 2 patients (both remained).
Impact of Treosulfan Dose and Combination With Other Agents on Transplantation Outcome
A higher treosulfan dose (42 vs 36 g/m 2 ) was associated with increased NRM for patients in CR1 in the univariate analysis. In an adjusted multivariate analysis, there was no impact of treosulfan dose on NRM. In addition, the treosulfan dose had no impact on acute or chronic GVHD, NRM, relapse, LFS, or OS.
Most patients received the combination of treosulfan and fludarabine, so we were unable to analyze the impact of treosulfan in combination with other agents on transplantation outcomes. There was no significant Abbreviations: GVHD, graft-versus-host disease; IP, interstitial pneumonitis; VOD, veno-occlusive disease of the liver (sinusoidal obstructive syndrome).
interaction between treosulfan dose (36 or 42 g/m 2 ) and disease status at transplantation. DISCUSSION TBI-based or busulfan-based ablative conditioning regimens are the most commonly used for patients with AML who undergo HCT, despite significant acute and late toxicities. [1] [2] [3] [4] 8, 9, [25] [26] [27] [28] [29] In recent years, new conditioning regimens have been explored to improve transplantation outcomes in AML. Treosulfan is a possible alternative to be used in conditioning regimens that have strong immunosuppressive and myelosuppressive effects in preclinical models. Both in vitro studies and in vivo human mouse models of treosulfan have demonstrated significant antileukemic activity, comparable to the activity of other chemotherapeutic agents. 11, 16, 30 In addition, treosulfan has a lower toxicity profile and the additional advantage of linear pharmacokinetics that do not require the monitoring of drug levels like busulfan. 11, 17, 19, 21, 23, 24, 31 Hepatotoxicity in our study was low. We observed VOD in only 2.2% of patients (with only 2 deaths related to VOD), similar to earlier reports from studies of treosulfan. 11, [32] [33] [34] [35] [36] [37] [38] Other myeloablative regimens reportedly were associated with higher VOD rates, especially with a combination of busulfan plus cyclophosphamide or when melphalan was added as a third drug. 10, 26, 28 In addition, the pulmonary toxicity profile of treosulfan-based regimens was low. Three patients died because of interstitial pneumonitis in our series (Table 5) , and 1 patient developed pulmonary dysfunction with VOD (patient survived). Historically, the reported incidence of pulmonary toxicity with TBI-based or busulfan-based regimens was up to 14% with high mortality. 27, 39, 40 This is noteworthy, because more than one-third of patients in our series had active/advanced disease, which is high risk for organ toxicities.
A recent, retrospective EBMT study 32 evaluated the toxicity profile and outcomes of 71 children with acute lymphoblastic leukemia who underwent HCT after a treosulfan-based conditioning with results that were similar to ours. Those investigators reported a high engraftment rate of 97%, comparable to the data presented here and to earlier studies that used treosulfan with low regimen-related toxicities. 11, [32] [33] [34] [35] [36] 38, 41 A very low incidence of graft rejection (only 1 event) and GVHD also was reported in a recent, large series of treosulfan-based, haploidentical HCT. 42 In that study, severe, acute GVHD (grade III or IV) was observed in 14% of patients, comparable to earlier treosulfan studies and our current findings (11%). 11, 32, 33, 35 The long-term outcomes of this large treosulfanbased series were 5-year OS and LFS rates of 38% and 33%, respectively. Outcomes correlated significantly with disease status at transplantation, as expected, similar to previous studies with TBI-based or busulfan-based conditioning regimens. Patients in CR1 had significantly better OS and LFS compared with patients in CR2 (Table 4) . A major cause of treatment failure was relapse in 31% of patients at 1 year and in 36% of patients at 2 years. The incidence of relapse was higher in patients beyond CR1 (Table 4) , resulting in a 5-year OS rate of 55% for patients who underwent transplantation in CR1, 37% for those who underwent transplantation in CR2, and 18% for those with active/advanced disease. These results are comparable to those reported from studies that used busulfanbased or TBI-based ablative conditioning regimens. 3, 4 Our data indicate that treosulfan is an effective conditioning regimen for HCT in patients who have AML in CR at the time of HCT, with a lower toxicity profile compared with that of conventional myeloablative conditioning regimens. This makes treosulfan-based regimens potentially applicable to older patients and/or patients with advanced disease. To our knowledge, this is the largest registry study of treosulfan-based conditioning in an AML cohort with data demonstrating comparable longterm outcomes with a low risk of early organ toxicity and acute GVHD compared with historic data using ablative regimens in AML. These results, which must be confirmed in prospective studies, indicate that treosulfan may represent a viable alternative to TBI-based or busulfanbased conditioning regimens.
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